ZADITEN TABLET 1 mg

Riik: Singapur

keel: inglise

Allikas: HSA (Health Sciences Authority)

Osta kohe

Infovoldik Infovoldik (PIL)
06-12-2012

Toimeaine:

KETOTIFEN HYDROGEN FUMARATE EQV KETOTIFEN

Saadav alates:

NOVARTIS (SINGAPORE) PTE LTD

ATC kood:

R06AX17

Annus:

1 mg

Ravimvorm:

TABLET

Manustamisviis:

ORAL

Retsepti tüüp:

Prescription Only

Valmistatud:

NOVARTIS PHARMACEUTICALS UK LTD

Loa andmise kuupäev:

1989-05-09

Infovoldik

                                 
 
 
 
ZADITEN
 
/ ZADITEN

 SRO 
Antihistamines for systemic use. 
DESCRIPTION AND COMPOSITION 
PHARMACEUTICAL FORM(S) 
Tablets (scored);  
SRO (slow release oral) film coated tablets;  
Syrup 
ACTIVE SUBSTANCE 
Zaditen tablets (scored) contain
the equivalent of 1 mg ketotifen (as the hydrogen fumarate). 
Zaditen SRO (slow release oral) tablets (film-coated) contains the
equivalent of 2 mg 
ketotifen (as the hydrogen fumarate). 
Zaditen syrup contains the equivalent of 1 mg ketotifen (as
the hydrogen fumarate) per 5 mL. 
ACTIVE MOIETY 
Ketotifen 
EXCIPIENTS 
Tablets contain lactose as an excipient (see section
SPECIAL WARNINGS AND 
PRECAUTIONS FOR USE). 
Syrup and oral solution contain maltitol liquid (hydrogenated
glucose syrup) as an excipient 
(see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE). 
For the full list of excipients, see section EXCIPIENTS. 
INDICATIONS 
Preventive treatment of bronchial asthma especially when
associated with atopic symptoms. 
Zaditen is not effective in aborting established attacks of
asthma. Zaditen is not a substitute 
for
corticosteroid treatment (inhaled or systemic) when corticosteroid is indicated in the 
treatment of asthma. 
Prevention and treatment of multisystem allergic disorders: 
  chronic urticaria  
  atopic dermatitis 
  allergic rhinitis and conjunctivitis 
Novartis   Page 
2 
Singapore Specific Package Leaflet  19 Sep 2011   
Zaditen/Zaditen SRO 
 
DOSAGE AND ADMINISTRATION 
USE IN ADULTS 
1 Zaditen SRO tablet (2 mg) in the evening, or
1 Zaditen tablet (1 mg) twice daily (with 
morning and evening meals). In patients susceptible to sedation,
slow increase in dose is 
recommended during the first week of treatment, starting with
½ tablet twice daily and 
increasing to the full therapeutic dose. If
necessary, the daily dose may be increased up to 4 
mg, i.e. 2 Zaditen SRO tab
                                
                                Lugege kogu dokumenti
                                
                            

Vaadake dokumentide ajalugu